Capital World Investors Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN

Capital World Investors decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,398,003 shares of the biopharmaceutical company’s stock after selling 600,363 shares during the period. Capital World Investors’ holdings in Regeneron Pharmaceuticals were worth $1,079,077,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after buying an additional 26,884 shares during the last quarter. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Regeneron Pharmaceuticals by 6.0% in the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after acquiring an additional 139,647 shares during the last quarter. Invesco Ltd. grew its position in Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after acquiring an additional 408,649 shares during the period. Finally, Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $1,012,296,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $635.45 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a 1-year low of $485.00 and a 1-year high of $821.11. The company has a market capitalization of $67.18 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 1.40 and a beta of 0.25. The business has a 50-day moving average of $706.93 and a 200-day moving average of $742.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same period last year, the business posted $8.22 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. Guggenheim raised their price target on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $792.65.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.